LMOD1 and neoplasm: This result suggests that ASPN, LMOD1, and MAB21L2 are key proteins that drive chemotherapy resistance and tumor recurrence in the dormant subgroup, and CRC patients with high expression of LMOD1, MAB21L2, and ASPN are at high risk of recurrence (Figures 5B–G).